What the reviews show
These reviews converge on one finding: the evidence for psychological benefit from youth gender medicine is of low or very low certainty. Reviews from McMaster University found 10 puberty-blocker studies and 24 cross-sex hormone studies in people under 26, none randomized, with every mental health and gender-distress outcome rated very low certainty (Miroshnychenko et al., 2025). The University of York reviews for England's Cass Review could draw no conclusions on how blockers affect gender distress or mental health, and found only moderate-quality evidence that mental health may improve during hormone treatment (Cass Review, 2024). A German update of NICE's search found no new qualifying blocker study (Zepf et al., 2024), and a US government umbrella review of 17 earlier reviews rated outcomes for distress, mental health, quality of life and regret as very weak for every intervention (U.S. Department of Health and Human Services, 2025). The WPATH-commissioned review rated all its hormone findings low-strength while reporting improvements in quality of life, depression and anxiety (Baker et al., 2021). Social transition showed neither benefit nor harm (Hall et al., 2024). Only short-term mastectomy complications reached high certainty (Miroshnychenko et al., 2024).
Guideline appraisals point the same way. Of 23 youth guidelines, only Sweden's and Finland's were recommended by all three raters, with WPATH scoring 35% for rigor of development (Taylor et al., 2024); a separate appraisal of WPATH's Standards of Care 8 rated overall quality about 3.5 to 4 out of 7 (Zhang et al., 2026).
Limits of the evidence
Reviews are only as strong as their underlying studies, which are overwhelmingly uncontrolled, small, short and affected by loss to follow-up. Regret and detransition reviews illustrate this: a pooled 1% surgical regret figure rests on follow-up often of one to two years and 36% attrition in the largest study (Bustos et al., 2021), while headline detransition ranges under 10% omit an included military study in which about 30% stopped hormones within four years (Feigerlova, 2025). Older Endocrine Society-commissioned reviews found too few cardiovascular events or fractures to assess risk (Maraka et al., 2017; Singh-Ospina et al., 2017). Funding and authorship are contested on both sides, from SEGM-funded McMaster reviews to WPATH's control over publication, and several searches end in 2021–2023. Low-certainty evidence signals uncertainty, not proof of no effect.